AgeX Therapeutics, a Juvenescence biotechnology company focused on therapeutics for human aging and regeneration, announced today, the theoretical foundation of the Company’s induced Tissue Regeneration (iTRTM) technology.
Juvenescence, a life sciences company utilizing expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human longevity.
Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.
Juvenescence is pleased to announce its latest equity investment in BYOMass, a Massachusetts-based company focused on central control of metabolism in the context of aging and age-related diseases.
Juvenescence and the Buck Institute for Research on Aging announce a new collaboration with the formation of BHB Therapeutics a joint venture.
Juvenescence is pleased to announce the close of the first tranche of its Series B financing, in the amount of $46 million.
Juvenescence, The Buck Institute for Research on Aging, and Insilico Medicine announced today that they have formed Napa Therapeutics, to develop drugs against a novel aging-related target.
Juvenescence has successfully raised $50 million in its Series A financing. The Series A financing was oversubscribed with participation from founders, insiders, institutional investors and family offices.